Q-omics provides the consensus-scored FBXO47 profile across patient tissues and cancer cell-line models. FBXO47 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FBXO47 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, FBXO47 RNA expression shows 12,240 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where FBXO47 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO47 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO47 survival associations across molecular data types. FBXO47 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO47 RNA expression–survival associations across cancer types. High FBXO47 expression shows unfavorable associations in UVM, LGG, THCA and READ, but favorable associations in DLBC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FBXO47 RNA expression.
This table summarizes FBXO47 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO47. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO47 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LUAD, LUSC and COAD. The LUAD box plot shows higher FBXO47 RNA expression in tumor versus normal tissue (log2 FC = +0.140, t-test p < 0.001).
This table shows molecular features associated with FBXO47 in patient tissues and cancer cell lines. In patient samples, FBXO47 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO47 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_SCLC.
